Validation and Evaluation of a Novel Cough Detection Device

When diagnosing chronic cough (cough lasting longer than 8 weeks), the physician nowadays very often relies on the patient's narrative and description. In our research project we want to find out whether a cough detector can continuously and reliably record the cough, how the user-friendliness of the cough detector is assessed and whether this continuous recording can support the physician in his diagnosis.

Study Overview

• Status: Completed
• Conditions: Chronic Cough
• Intervention / Treatment: Device: SIVA-P3

Detailed Description

After chronic cough diagnosis, the Principal Investigator (or his designee) will identify patients who are potentially eligible to participate in this pilot study, based on the predefined inclusion criteria.

A number of 25 participants will be recruited for this pilot study: 10 suffering from chronic cough with unclear underlying cause, 4-6 suffering from COPD, 4-6 suffering from Asthma and 4-6 suffering from interstitial lung disease.

Patients who choose to participate will be entered into the pilot study after obtaining their informed consent, when they will receive the SIVA-P3 wearable (and charging device), helped to download the SIVA-P3 smartphone application and couple the wearable component with the smartphone.

Furthermore, they will be asked to rate their current cough severity on a visual analog scale (Cough Severity VAS). Participants will receive an envelope with a second Cough Severity VAS and a return envelope to send back the SIVA-P3 wearable and charging device at the end of the study.

Participants will receive standard care and will be asked to wear the wearable component during the day, charge it on the bedside while sleeping and to otherwise go about daily life as they would do normally for a duration of seven days. In the evening of every day, they will be prompted by the SIVA-P3 smartphone application to indicate the timing of their main meals.

On day 8, the study nurse will conduct a pre-scheduled phone interview with each participant. The phone interview will include instructing the patient to fill in the final Cough Severity VAS, asking the questions of the Participant User Feedback Questionnaire, and instructing the patient to send the Cough Severity VAS form and the SIVA-P3 wearable (and charging device) back to the trial site using the return envelope. The Participant User Feedback Questionnaire will include ratings of wearing comfort, usability and likeliness to wear for extended period of time.

• Study Type: Interventional
• Enrollment (Actual): 29
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Switzerland
  • Zurich, Switzerland, 8091
    • University Hospital Zurich

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Informed Consent as documented by signature
• Men and women, aged 18 and over at date of signing the Informed Consent Form
• Patients diagnosed with a chronic cough of unknown origin or COPD or Asthma or with interstitial lung disease.
• Attending the treatment procedure as an outpatient
• Using a smartphone (minimal version: iOS 13 / Android 10) on a daily basis and willing to install SIVA-P3 smartphone application
• Adequate communication in German or Swiss-German (all study documentation and SIVA-P3 will be set to German language only).

Exclusion Criteria:

• Unable to make the decision to participate in a clinical study (e.g. seriously ill or unconscious subject, or subject with a mental or intellectual disability)
• Inability to follow the procedures of the study, e.g. due to physical or intellectual impairment precluding informed consent or protocol adherence, psychological disorders (excluding depression) or dementia
• Use of any other medical device equipment (e.g. portable oxygen concentrator, artificial cardiac pacemaker, implantable cardioverter-defibrillator)
• Pregnancy: Female participants in child-bearing age without a negative pregnancy test (urine test). Female participants who are neither surgically sterilized / hysterectomized nor post-menopausal for longer than 2 years are considered as being of childbearing potential.Known or suspected non-compliance, drug or alcohol abuse
• Participation in another clinical study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Intervention Arm; The experimental intervention uses the SIVA-P3 system, the prototype of a digital solution aiming to support the diagnostic process in cases of chronic cough. The SIVA-P3 system primarily consists of a wearable audio and movement recorder and a smartphone app for the patient.

Device: SIVA-P3; Digital cough recording: Participants receive a small, wearable data recorder, wear it during waking hours and keep it on the nightstand during sleep for 7x24 hours. The data is sent to a smartphone application, where a cough detection algorithm converts it into time-stamped cough events. Participants respond to questions on their smartphone once a day for additional context data. The cough events and context data are sent to a secure online database for further evaluation. For the first 24 hours, segments of audio data are sent to be able to validate the performance of the cough detection algorithm. Afterwards, only cough events and context data are sent from the participant's smartphone.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Validation	The primary outcomes are sensitivity, specificity and related metrics (positive and negative predictive values, rates of false positive and false negative detections per hour) for cough frequency measurement of SIVA-P3 in the target patient population over a 24-hour validation phase (first 24 hours after baseline visit). Sensitivity, specificity and positive and negative predictive values contribute to a description of cough monitor performance.	24 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Wearing Time	The wearable device continuously records movement data. This movement data is used to determine if the wearable device is being worn.	7 days
Wearing Comfort	Wearing Comfort will be determined through quantitative analysis of closed and open questions in the Participant User Feedback Questionnaire.	7 days
Awareness of wearing the device	Patients will be questioned via the smartphone application how many times they have approximately noticed during the day that they have been wearing the device.	7 days
Usability	Usability from the patient's perspective will be determined through quantitative analysis of closed questions in the Participant User Feedback Questionnaire.	7 days
Continued Wearing Likeliness	Continued Wearing Likeliness will be determined through quantitative analysis of closed and open questions in the Participant User Feedback Questionnaire.	7 days
Correlation of patient-reported cough severity	Cough Severity Correlation will be determined by correlating daily cough counts determined by the SIVA-P3 algorithm with the patient's self-reported Cough Severity VAS.	7 days
Variations of time course of coughing between different days within individual patients	To compare the variations of time course of coughing, the hourly profiles of each day will be interpreted as discrete distribution functions. A range of statistical features associated with properties of distributions will be calculated for all profiles and compared both within individual patients and across the whole population. These features will include mean, median, variance, skewness, kurtosis and additional descriptive statistics for multimodal distributions.	7 days
Diagnostic prediction models	To evaluate the predictive performance of a mathematical model, different models will be explored. The outcome is the performance of the best predictive model identified.	7 days

Collaborators and Investigators

• Sponsor: Evoleen AG
• Collaborators: University Hospital, Zürich
• Investigators: Principal Investigator: Christian Clarenbach, PhD. Dr. med., University of Zurich

Study record dates

Study Major Dates

• Study Start (Actual): April 22, 2021
• Primary Completion (Actual): October 26, 2021
• Study Completion (Actual): October 26, 2021

Study Registration Dates

• First Submitted: April 20, 2021
• First Submitted That Met QC Criteria: April 22, 2021
• First Posted (Actual): April 27, 2021

Study Record Updates

• Last Update Posted (Actual): November 23, 2021
• Last Update Submitted That Met QC Criteria: November 22, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Respiration Disorders; Signs and Symptoms, Respiratory; Cough
• Other Study ID Numbers: SIVA-PS1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No